Is Face Mask with Face Shield More Effective than Face Mask Alone in Reducing SARS-CoV-2 Transmission? A Systematic Review

Germana Emerita V. Gregorio, MD, PhD,¹ Maria Teresa Sanchez-Tolosa, MD,^{2,3,4} Maria Cristina Z. San Jose, MD,^{5,6} Myzelle Anne Infantado, PTRP,⁷ Valentin C. Dones III, PhD⁸ and Leonila F. Dans, MD, MSc²

> ¹Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, College of Medicine and Philippine General Hospital, University of the Philippines Manila ²Department of Clinical Epidemiology, College of Medicine and Philippine General, University of the Philippines Manila ³University of the East Ramon Magsaysay Memorial Medical Center Inc. (UERMMMCI) ⁴St. Luke's Medical Center College of Medicine – William H. Quasha Memorial (SLMCCM-WHQM) ⁵Department of Neurosciences College of Medicine and Philippine General Hospital, University of the Philippines Manila ⁶Institute for Neurosciences, St Luke's Medical Center, Quezon City ⁷Child Development Enrichment Center Medical Center Manila ⁸Center for Health Research and Movement Science of the College of Rehabilitation Sciences, University of Santo Tomas

ABSTRACT

Background. The use of face shield in addition to face mask is thought to reduce the transmission of SARS-CoV-2 by blocking respiratory droplets and by preventing one from touching facial orifices.

Objective. To determine the effectiveness of face mask with face shield, compared to face mask alone, in reducing transmission of SARS-CoV-2.

Methods. We searched MEDLINE, Cochrane Library, as well as trial registers, preprint sites and COVID-19 living evidence sites as of 30 September 2021. We included studies that used face shield with face mask versus face mask alone to prevent COVID-19. We screened studies, extracted data, assessed the risk of bias and certainty of evidence using the GRADE approach. Review Manager 5.4 was used to estimate pooled effects.

Results. There is no available direct evidence for face shield plus face mask versus face mask alone in the general public. Five (5) observational studies with very low certainty of evidence due to serious risk of bias and indirectness were included. Participants in all the studies were health care workers (HCWs) who used the face shield with their standard personal protective equipment (PPE). Four (4) of the studies were in the hospital setting (three case control studies, one pre- and post-surveillance study); one was done in the community (one pre- and post-surveillance study) in which HCWs visited the residence of the contacts of SARS-CoV-2 positive patients. The case control studies done in the hospital setting showed a trend toward benefit with the use of face shield or goggle but this was inconclusive (OR 0.85, 95% CI 0.68-1.08) while the pre- and post-surveillance study showed significant benefit when face shield (OR 0.28, 95% CI 0.22-0.37) use became a requirement for HCWs upon hospital entry. In the study done in the community setting, significant protection for HCWs was noted with the use of face shield (OR 0.04, 95% CI 0.00-0.69) but the results were limited by serious risk of bias and imprecision.

Conclusion. In the hospital setting, there was a lower likelihood of COVID-19 infection in HCWs who used a face shield or goggles on top of their PPE. For the general public in the community, there is presently no study on the use of face shield in addition to the face mask to prevent COVID-19 infection.

Keywords: personal protective equipment, COVID-19, face mask, surgical mask, face shield, goggles, eye visor, eye protector

Corresponding author: Germana Emerita V. Gregorio, MD, PhD Division of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pediatrics, College of Medicine and Philippine General Hospital University of the Philippines Manila Taft Avenue, Ermita, Manila 1000, Philippines Email: gvgregorio@up.edu.ph

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mainly transmitted through respiratory droplets and close contact, with a concern for airborne transmission especially during aerosol-generating procedures. In SARS-CoV-2, SARS or MERS, a reduced risk of infection was observed using surgical or 12-16 layer cotton masks (OR=0.15, 95% CI 0.07-0.34). There was also significant protection with the use of eye protectors (OR=0.22, 95% CI 0.12-0.39), translating to 78% relative risk reduction.¹ Using face shield was found to reduce the potential for autoinoculation by preventing one from touching the front and side of the face, and protecting viral entry into the eyes, nose and mouth.² However, respiratory droplets may enter through the large gaps at the open-top, at the bottom, and the sides of the face shield. When a face shield was combined with a face mask, it is unknown which of the two is better in preventing SARS-CoV-2 transmission.1 The objective of this report is to determine the effectiveness of face mask with face shield, compared to face mask alone, in reducing transmission of SARS-CoV-2.

METHODS

We comprehensively searched various electronic databases that included MEDLINE via PubMed, Cochrane Library, ChinaXiv, MedRXIV, BioRXIV, as well as the following registries for ongoing and completed trials: ClinicalTrials.gov (USA); ChiCTR.org. (China); and the International Clinical Trials Registry Platform (ICTRP, WHO). We also searched for published or ongoing studies on COVID-NMA, the COVID-19 Open Living Evidence Synthesis: https://covid-nma.com/ and the COAP Living Evidence on COVID-19. The last search date was September 30, 2021 using a combination of subject headings and keywords based on population, intervention, comparator, outcome (PICO): P - general public; I - face shield with face mask, face shield; C - no face shield; and O - prevalence of SARS-CoV-2 transmission. (Appendix 1). We included any type of study investigating the effects of face shield or face mask on the incidence of SARS-COV-2 infection. We checked the reference lists of included papers and relevant systematic reviews. We also did a free search of online sources, preprint articles, and various coronavirus resource centers. We screened abstracts, reviewed full texts and extracted relevant information on study design, settings, population and outcomes. There was no language restriction. We screened studies, extracted data, assessed the risk of bias and certainty of evidence using the GRADE approach. Disagreement was settled by a third reviewer. Review Manager 5.4 was used to estimate pooled effects.

RESULTS

There was no available direct evidence for face shield plus face mask versus face mask alone in the general public.

Five (5) observational studies with very low certainty of evidence due to serious risk of bias and indirectness were found among health care workers (HCWs) who used the face shield with their standard personal protective equipment (PPE).

A summary of the included studies (three case control and two pre- and post-surveillance studies)³⁻⁷ is shown in Appendix 2 and the critical appraisal is shown in Appendix 3. There were issues related to representativeness, selection of controls, and ascertainment of exposure. The overall certainty of the evidence was judged to be very low (Appendix 4).

The three case-control studies³⁻⁵ included in this review enrolled a total of 1164 healthcare workers in a hospital and/or healthcare setting. Of these, 608 used or always used face shield or goggle while 556 did not use or did not always use face shield or goggle. In the former group, 295 tested positive for COVID-19; in the latter, 291 had positive results. The pooled estimate for the outcome of COVID-19 infection showed a trend toward benefit with the use of face shield or goggles, but this was inconclusive (OR 0.85, 95% CI 0.68-1.08) (Appendix 4 and Appendix 5).

The pre- and post-surveillance study of Mojajer et al.⁶ done in a healthcare setting reported that before the use of face shield was instituted in their hospital, 166 individuals out of 2486 tested had positive RT-PCR results. After the hospital-wide directive on face shield use, only 80 of the 4041 tested were positive on RT-PCR. This study showed significant benefit in using face shield (OR 0.28, 95% CI 0.22-0.37); however, the certainty of the evidence was very low because of serious risk of bias and indirectness (Appendix 4 and Appendix 5).

The pre-and post-surveillance study done in the community by Bhaskar and Arun⁷ involved 62 healthcare workers serving in the community. Before using face shield, 12 of the healthcare workers contracted COVID-19. After the initiation of face shield use, none of the remaining 50 contracted the infection. While the data showed significant protection with the use of face shield (OR 0.04, 95% CI 0.00-0.69), the certainty of the evidence was assessed to be very low because of very serious risk of bias, imprecision and indirectness.

DISCUSSION

There was no direct evidence to answer the question whether among the general public, face mask with face shield versus face mask alone is protective against COVID-19 infection. In the five studies cited in this review, the sample population was all on HCWs who used the face shield with their standard PPEs. Four of the studies³⁻⁶ were in the hospital setting; and one in the community⁷ in which HCWs visited the residence of SARS-CoV-2 positive patients to counsel asymptomatic family contacts.

SARS-CoV-2 is highly infectious and the main route of transmission is via respiratory or aerosol droplets. An infected patient is the main source of transmission, even in the asymptomatic stage and this could be spread through close person-to-person contact during talking, coughing, sneezing and singing.8 The infected droplet may lodge in the mucous membrane of the eyes or on parts of the face not covered by the mask, infecting another person. This is the rationale on using an eye protector which may either be a face shield, goggle or a visor primarily if the suggested physical distancing of at least 1 meter is not maintained. In our review, very low certainty of evidence showed that using an eye protector effectively prevents of SARS-CoV-2 infection among HCWs. Our results are similar to a previous study in SARS-CoV, also a viral respiratory illness caused by the coronavirus, in which there was an increased risk of SARS infection in those who never wore goggle while operating on a SARS positive patient (OR 4.05 95% CI 0.54-30.34).9 Another case-control study identified potential risk factors for SARS among HCWs. Of the 56 potential factors, using a face shield was protective (OR 0.499 95% CI 0.270-0.749) on univariate analysis but not on multivariate analysis.¹⁰

A simulation study¹¹ quantified the health risk posed by infectious droplets and percentage reduction in exposure provided by face shield and face mask. Using two mannequin heads placed one meter apart, aerosols of different sizes were generated and a particle counter was used to evaluate face mask and face shield performance. The reduction factor of the total particles aspirated was lower when the receiver used a face mask than the face shield (21.8% versus 54.8%, p = 0.002). If the emitter wore a protective device, either a face mask or face shield, the level of received particles was reduced by 96.8% (p = N.S.). When both the emitter and receiver wore a face mask or a face shield, there was a 97.3% and 98% reduction, in the number of particles transmitted, respectively (p = 0.001). When receiver and emitter wore a face mask or a face shield, the face shield performed significantly better with a reduction factor of 97.7% versus 96.8% for the face mask in the range of <0.3 µm particles (p = 0.01); 97.8% versus 97.1% for the face mask in the range of 0.3–0.5 μ m (p = 0.052 NS). For particles over 1 μ m in size, face masks and face shields worn by the emitter and the receiver reduced the number of inhaled particles by over 99%.

In the community setting, using an eye protector and a face mask in the prevention of SARS-CoV-2 infection is debated in the mainstream media and by public health authorities. The evidence that was used during the initial¹² and present recommendation was the same – the study⁷ done in the community setting with HCWs wearing the face shield while counselling household members of COVID infected patients. In the initial review done in May 2021, it was considered that the face shield provided additional mechanical protection with a face mask against SARS- CoV-2 transmission. especially in high-risk environments such as crowded public transit, poorly ventilated spaces, and thus, suggested the use of face shield with face mask in areas with sustained community transmission of infection. In the present review done in September 2021, other factors related to using face shield were considered including public preference and compliance, additional cost, vaccination rates and environmental concerns with plastic disposal (Appendix 6). During the consensus panel with infectious disease specialists and other stakeholders, it was decided that using a face shield with a face mask will only be recommended in areas with sustained community transmission. It will no longer be required for the general public in non-health care setting. Moreover, the meta-analysis of Chu¹ showed a 78% reduction in MERS and SARS transmission with the use of an eye protector by HCWs. All 13 studies cited were performed in a hospital. In this setting, there is a higher risk of infection due to direct contact with severe and critically ill patients, use of aerosol generating procedures and with limited ventilation in an enclosed area.

CONCLUSION

In summary, this review presented the available evidence on the use of eye protector in addition to the face mask and other standard PPE. Very low certainty evidence has shown that an eye protector is effective in preventing COVID-19 infection among HCWs. However, there is presently insufficient evidence to require the addition of an eye protector in addition to face mask among the general public in the non-health care setting. There is presently a need for more studies on the use of face shield in addition to face mask as protection against COVID-19 infection for the general public in the community during the pandemic.

Recommendations from Other Groups

The Center for Disease Control¹³ as of 19 April 2021, recommends the use of masks in addition to staying at least 6 feet apart in the following situations: (1) when indoors around people who don't live in the same household; (2) traveling on a plane, bus, train, or other form of public transportation traveling into, within, or out of the United States and in U.S. transportation hubs such as airports and stations; (3) in public settings and when around people who don't live in the same household; and (4) inside the house if a household member is sick with symptoms of COVID-19 or has tested positive for COVID-19. Goggles or other eye protection may be used in addition to a mask.

The World Health Organization,¹⁴ as of 01 December 2020, recommends the use of mask in areas where the virus is circulating, when at least 1 meter distance from others is not possible, poor or unknown ventilation which depends on the rate of air change, recirculation and outdoor fresh air. There was no recommendation made on the use of face shield.

The Interagency Task Force¹⁵ for the Management of Emerging Infectious Disease, as of 14 December 2020, recommends that all persons are mandated to wear fullcoverage face shields together with face masks, ear-loop masks, indigenous, reusable, or do-it-yourself masks, or other facial protective equipment which can effectively lessen the transmission of COVID-19, whenever they go out of their residences. On 23 September 2021, this was amended to limit the use of face shields, on top of face mask, in highrisk activities in closed, crowded areas and if with close contact. On 16 November 2021, the use of face masks with face shield was limited to areas with sustained community transmission of the virus.

Statement of Authorship

All authors contributed in the conceptualization of work, acquisition and analysis of data, drafting and revising the manuscript, and approved the final version submitted.

Author Disclosure

All authors declared no conflicts of interest.

Funding Source

The study was funded by the Department of Health - Republic of the Philippines.

REFERENCES

- Chu D, Akl E, Duda S, Solo K, Yaacoub S, Schünemann H. Physical distancing, face masks, and eye protection to prevent person-toperson transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87.
- Perencevich E, Diekema D, Edmond M. Moving personal protective equipment into the community: face shields and containment of COVID-19. JAMA. 2020;323(22):2252-3.
- Khalil M, Alam M, Arefin M, Chowdhury M, Huq M, Chowdhury J. Role of personal protective measures in prevention of COVID-19 spread among physicians in Bangladesh: a multicenter cross-sectional comparative study. SN Compr Clin Med.2(10):1733-9.
- Chatterjee P, Anand T, Singh K, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A casecontrol investigation in the time of COVID-19. Indian J Med Res. 2020;151(5):459-67.

- Rodriguez-Lopez M, Parra B, Vergara E, Rey L, Salcedo M, Arturo G, et al. A case-control study of factors associated with SARS-CoV-2 infection among healthcare workers in Colombia. BMC Infect Dis. 2021;21(1):878.
- Mohajer M, Panthagani K, Lasco T, Lembcke B, Hemmige V. Association between universal face shield in a quaternary care center and reduction of SARS-COV-2 infections among healthcare personnel and hospitalized patients. Int J Infect Dis. 2021; 105:252-5.
- Bhaskar M, Arun S. SARS-CoV-2 infection among community health workers in India before and after use of face shields. JAMA. 2020;324(13):1348.
- Karia R, Gupta I, Khandait H, Yadav A, Yadav A. COVID-19 and its Modes of Transmission. SN Compr Clin Med. 2020 Sep 1:1-4. doi: 10.1007/s42399-020-00498-4. Epub ahead of print. PMID: 32904860; PMCID: PMC7461745.
- Chen WQ, Ling WH, Lu CY, Hao YT, Lin ZN, Ling L, Huang J, Li G, Yan GM. Which preventive measures might protect health care workers from SARS? BMC Public Health. 2009 Mar 13; 9:81. doi: 10.1186/1471-2458-9-81. PMID: 19284644; PMCID: PMC2666722.
- Pei LY, Gao ZC, Yang Z, Wei DG, Wang SX, Ji JM, Jiang BG. Investigation of the influencing factors on severe acute respiratory syndrome among health care workers. Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Jun 18;38(3):271-5. PMID: 16778970.
- Wendling JM, Fabacher T, Pébaÿ PP, Cosperec I, Rochoy M. Experimental Efficacy of the Face Shield and the Mask against Emitted and Potentially Received Particles. Int J Environ Res Public Health. 2021 Feb 17;18(4):1942. doi: 10.3390/ijerph18041942. PMID: 33671300; PMCID: PMC7922468.
- 12. San Jose MS, Dones V, Gregorio G, Tolosa M: Should facemask plus face shield be used rather than facemask alone to reduce SARS COV2 transmission? Philippine Society for Microbiology and Infectious Diseases: Philippine Society for Microbiology and Infectious Diseases [internet]. 2021 [cited 2021 May]. Available from: https:// www.psmid.org/face-shield-plus-face-mask-evidence-summary/.
- Center for Disease Control: Guidance on Wearing Mask [Internet]. 2021 [cited 2021 April]. Available from: https://www.google.com/ search?q=cdc+guidelines+on+face+shield+use&oq=&aqs=chrome. 0.35i39i362l8...8.61857611j0j15&sourceid=chrome&ie=UTF-8.
- World Health Organization: Masks [internet]. 2020 [cited 2020 Dec]. Available from: https://www.who.int/emergencies/diseases/novelcoronavirus-2019/question-and-answers-hub/q-a-detail/coronavirusdisease-covid-19-masks.
- Inter-Agency Task Force: Management of Emerging Diseases [internet]. 2021 [cited 2021 Sept]. Available from: https://www.pna. gov.ph/articles/1154380.

APPENDICES

Appendix 1. Search Yield and Results

- ((("COVID-19" [Supplementary Concept] OR "COVID-19 diagnostic testing" [Supplementary Concept] OR "COVID-19 drug treatment" [Supplementary Concept] OR "COVID-19 serotherapy" [Supplementary Concept] OR "COVID-19 vaccine" [Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept] OR "2019-nCoV" OR "2019nCoV" OR "cov 2" OR "Covid-19" OR "sars coronavirus 2" OR "sars cov 2" OR "SARS-CoV-2" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus 2" OR "COVID 19" OR "COVID-19" OR "2019 ncov" OR "2019nCoV" OR "corona virus disease 2019" OR "cov2" OR "COVID-19" OR "COVID19" OR "COVID-19" OR "2019 ncov" OR "2019nCoV" OR "corona virus disease 2019" OR "cov2" OR "COVID-19" OR "COVID19" OR "ncov" OR "new corona virus" OR "new coronaviruses" OR "novel corona virus" OR "novel coronaviruses" OR "SARS Coronavirus 2" OR "SARS2" OR "SARS-COV-2" OR "Severe Acute Respiratory Syndrome Coronavirus 2") OR ((19[tiab] OR 2019[tiab] OR "2019-nCoV" OR "Beijing" OR "China" OR "Covid-19" OR epidem*[tiab] OR epidemic* OR epidemy OR new[tiab] OR "novel"[tiab] OR "outbreak" OR pandem* OR "SARS-CoV-2" OR "Shanghai" OR "Wuhan") AND ("Coronavirus Infections"[Mesh] OR "coronavirus"[MeSH Terms] OR coronavirus*[all] OR corona-virus*[all] OR cov[tiab] OR pneumonia-virus*[tiab]))) AND 2019/12/1:3000/12/31[PDAT])
- 2. (((systematic review[ti] OR systematic literature review[ti] OR systematic scoping review[ti] OR systematic narrative review[ti] OR systematic qualitative review[ti] OR systematic evidence review[ti] OR systematic qualitative review[ti] OR systematic mixed studies review[ti] OR systematic mapping review[ti] OR systematic cochrane review[ti] OR systematic search and review[ti] OR systematic integrative review[ti]) NOT comment[pt] NOT (protocol[ti] OR protocols[ti])) NOT MEDLINE [subset]) OR (Cochrane Database Syst Rev[ta] AND review[pt]) OR systematic review[pt]
- 3. Masks OR "respiratory devices" OR "respiratory protective devices" OR "filtering facepiece respirators" OR "respiratory protective devices" OR N95 OR "face mask" OR "surgical mask" OR "medical masks" OR "N95 respirator" OR "filtering facepiece respirator"

4. face shield or eye goggles or eye protector

Appendix 2. Included Studies on the Use of Face Shield Among Health Care Workers

| Study | Setting | Population | COVID (+) | COVID (-) | Intervention | Comparator | Outcome |
|--------------------|----------------------|---|-----------|-----------|--|---|--|
| Khalil SN | Dhaka, Bangladesh | 190 Medical staff in 19 health facilities | 98 | 92 | Face shield | No face shield | Number of HCW with face shield infected with COVID-19 |
| Mojajer A | Houston, Texas | 6527 HCP of a quarternary health hospital | 246 | 6281 | Face shield ¹ with standard PPE | Standard PPE | Number of HCP infected before and after implementation of use of face shield with standard PPE Number of HCP with HAI before and after implementation of use |
| | | | | | | | of face shield with standard PPE |
| Bhaskar | India | 112 HCW | 12 | 100 | Face shield and PPE | PPE alone | Number of HCW with COVID-19 before and after implementation of use of face shield with PPE |
| Chatterjee | India | 751 symptomatic HCW | 378 | 373 | Use of face shield or goggles (either or both) | No face shield/goggles | Number of HCW with face shield infected with COVID-19 |
| Rodriguez Lopez | Cali, Colombia | 223 HCW with or without symptoms | 120 | 103 | Use of face shield/goggles always | Use of face shield/goggles not always | Number of HCW with face shield infected with COVID-19 |

¹ Face shield used was a Lazarus 3D (Corvallis, OR, USA)

² Personal protective equipment included alcohol hand rub, 3-layered surgical masks, gloves, and shoe covers and physical distancing

Abbreviation: HCW - health care workers; HCP - health care personnel; HAI - hospital acquired infection; PPE - personal protective equipment

| Case control studies | Khalil 2020 | Chatterjee 2020 | Rodriguez-Lopez 2021 |
|--|--|--|---|
| Selection | | | |
| ls case definition adequate | Yes (RT PCR +) | Yes (RT PCR+) | Yes (RT PCR+) |
| Representatives of the cases | Not stated how they were selected from the list | Not stated how they were selected from the data portal | Selected by random sample from those identified as HCW with or without symptoms |
| Selection of control | Not stated how they were selected from the list | Not stated how they were selected from the data portal | Selected by random sample from those identified as HCW with or without symptoms |
| Definition of control | Yes (RT PCR -) | Yes (RT PCR -) | Yes (RT PCR -) |
| Comparability | | | |
| Comparability of cases and controls on the basis of the design and analysis | Yes (Cases and controls were selected on the basis of their RT PCR tests). No difference in the baseline characteristics of cases and controls | Yes (Cases and controls were selected on the basis of their RT PCR tests). In those who were positive, there were more males and with duration of work in the workplace >1 year) | Yes (Cases and controls were selected on the basis of their RT PCR tests); There were more COVID positive who were males, worked in high risk areas and night shift |
| Exposure | | | |
| Ascertainment of Exposure | Information was obtained online thru a Google form using a predesigned structured questionnaire | No statement that the telephone interviewer was blinded to COVID status of the interviewee (no interviewer variability was reported) | Data collected by two trained researchers by telephone interview using structured questionnaire who were blinded to the COVID status of the subject. However, recall bias might still exist |
| Same method of ascertainment for cases and controls | Yes (thru questionnaire) | Yes (telephone interview) | Yes (telephone interview) |
| Non response rate | All patients accounted for | Only 64% response rate | All patients accounted for |

Appendix 3. Detailed Appraisal of Included studies, using Newcastle Ottawa Scale

| Cohort studies | Bhaskar 2020 | Mojajer 2021 |
|---|--|---|
| Selection | | |
| Representative of the exposed cohort | Yes (after the face shield was implemented) | Yes (after the face shield was implemented) |
| Selection of the non exposed cohort | Yes (before the face shield was implemented) | Yes (before the face shield was implemented) |
| Ascertainment of exposure | Self report by signs and symptoms and COVID PCR test | Data was obtained from the surveillance clinic (but not stated whether this was electronic data or medical records) |
| Demonstration that outcome of interest was not present at the start of the study | Yes. All of them were COVID (-) before the community work | Yes. HCW who were previously COVID (+) were excluded |
| Comparability | | |
| Comparability of cohorts on the basis of design or analysis | Study controls were those who did not wear face shield in working in the community | Pre-surveillance was the period before face shield was implemented with face mask |
| Outcome | | |
| Assessment of outcome | Self report and thru COVID-19 PCR test | COVID-19 PCR test |
| Was follow up long enough for outcome to occur? | Yes as two weeks follow up sufficient to know whether they have developed COVID | Yes as two weeks follow up sufficient to know whether they have developed COVID |
| Adequacy of follow up | All subjects accounted for | All subjects accounted for |

Appendix 4. GRADE Evidence Profile: Face Shield Compared to No face shield for health care workers

A. Case control studies

Bibliography

- 1. Khalil M, Alam M, Arefin M, Chowdhury M, Huq M, Chowdhury J. Role of personal protective measures in prevention of COVID-19 spread among physicians in Bangladesh: a multicenter cross-sectional comparative study. SN Compr Clin Med.2(10):1733-9.
- 2. Chatterjee P, Anand T, Singh K, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151(5):459-67.
- 3. Rodriguez-Lopez M, Parra B, Vergara E, Rey L, Salcedo M, Arturo G, et al. A case-control study of factors associated with SARS-CoV-2 infection among healthcare workers in Colombia. BMC Infect Dis. 2021;21(1):878.

| | Certainty assessment | | | | | | | | Effect | | | 1 |
|--|-------------------------------|------------------|--------------------|-------------------|------------------|--|---|-------------------|------------------------------|---|------------------|-----------------|
| No. of studies | Study design | Risk of bias | Inconsis- tency | Indirect- ness | Impre- cision | Other consi- derations | Face Shield | No Face Shield | | Absolute (95% CI) | Certainty | Impor- tance |
| COVID 19 In | ection (as | sessed wit | th: RT PCR) | | | | | | | | | |
| 586 cases; 578 controls 295/608 exposed | obser- vational studies | very seriousª | serious⁵ | serious | not serious | strong associ- ation all plau- sible residual confounding | 586 cases 578 controls 295/608 exposed 291/556 unexposed | | OR 0.85 (0.68 to 1.08) | (0.68 to | ⊕000 VERY LOW | |
| 291/556 unexposed (3 studies) | | | | | | would reduce the demon- strated effect | - | 0.0% | - | 0 fewer per 1,000 (from 0 fewer to 0 fewer) | | |

CI: confidence interval; OR: odds ratio

Explanations

^a Compliance with face shield use and other health protocols was not assessed; some studies were based on interview or structured questionnaire and may have caused recall bias

^b Research question should answer Use of Face shield and face mask vs Face mask alone

 $^{\rm c}$ Considerable heterogeneity (I²=92%) with overlap on the confidence intervals of the studies

B. Pre- and post-surveillance study among health care workers

Bibliography

- 1. Mojajer M, Panthagani KM, Lasco T, Lembcke B, Hemmige V. Association between universal face shield in a quaternary care center and reduction of SARS-COV-2 infections among healthcare personnel and hospitalized patients. International JJournal of Infectious Diseases. 2021 Apr;105:252–5.
- 2. Bhaskar ME, Arun S. SARS-CoV-2 Infection Among Community Health Workers in India Before and After Use of Face Shields. JAMA. 2020 Oct 6;324(13):1348.

| | | Certa | nty assessment | | | No. of patients | | Effect | | | | |
|-----------------------------------|-----------------------------|------------------|--------------------|------------------------------|------------------------------|---------------------------|-------------------|--------------------|------------------------------|--|------------------|-----------------|
| No. of studies | Study design | Risk of bias | Inconsis- tency | Indirect- ness | Impre- cision | Other consi- derations | Face Shield | No Face Shield | Relative (95% CI) | Absolute (95% CI) | Certainty | Impor- tance |
| In the Hospite | al Setting - | - COVID- | 19 Infectio | n (assessea | l with CO | VID-19 RT-PC | R) | | - | | | |
| 6527 participants (1 study) | obser- vational study | seriousª | not serious | very serious ^b | not serious | strong association | 80/4041 (2.0%) | 166/2486 (6.7%) | OR 0.28 (0.22 to 0.37) | 48 fewer per 1,000 (from 52 fewer to 42 fewer) | ⊕OOO VERY LOW | |
| In the Comm | unity Settin | ng - COV | ID-19 Infe | ction (asses | sed with | COVID-19 RT- | PCR) | | | | | |
| 112 participants (1 study) | obser- vational study | very seriousª | not serious | very serious [♭] | very serious ^c | none | 0/50 (0.0%) | 12/62 (19.4%) | OR 0.04 (0.00 to 0.69) | 186 fewer per 1,000 (from 60 fewer to –) | ⊕000 VERY LOW | |

CI: confidence interval; RR: risk ratio


Explanations

^b Study was not done in the general population but among healthcare workers. Research question should answer Use of Face shield and face mask vs

Face mask alone

^c Very wide confidence interval

^a Compliance with face shield use and other health protocols was not assessed



Appendix 5. Forest plots. (A) Case control studies. (B) Pre- and post-surveillance study among health care workers. (B-1) In the hospital / health setting. (B-2) In the community setting.

| Factors | | | Judgement | | Research evidence/additional considerations from panel members | | | |
|--|--|--|---|---|---|---|--|--|
| Problem | No | Yes (8) | | | | · | | |
| Benefits | Large (3) | Moderate (3) | Small (1) | Uncertain (1) | | NO EVIDENCE for the reduction of risk in the general public BENEFIT among healthcare workers in both hospital (OR 0.28, 95% CI 0.23-0.37) and community settings; INCONCLUSIVE BENEFIT from 3 cohort studies among HCW in hospital These PPE can prevent transmission of other respiratory infectious organisms | | |
| Harm | Large (2) | Small (6) | Uncertain | Varies | | OR 0.85, 95% CI 0.68 – 1.08: Tendency to have minimal risk of COVID-19 infection among HCW in the hospital setting | | |
| Certainty of evidence | High | Moderate (2) | Low (4) | Very low (2) | | • The overall certainty of evidence: VERY LOW | | |
| Balance of effects | Favors drug (4) | Does not favor drug | Uncertain (4) | Varies | | | | |
| Values | Important uncertainty or variability (3) | Possibly important uncertainty or variability (3) | Possibly NO important uncertainty or variability (2) | No important uncertainty or variability | | | | |
| Resources required | Uncertain | Large cost (1) | Moderate Cost (6) | Negligible cost (1) | Moderate Lar savings savi | 0 | | |
| Certainty of evidence of required resources | No included studies (5) | Very low (2) | Low (1) | Moderate | High | No cost-effectiveness studies available. | | |
| Cost effectiveness | No included studies (6) | Favors the comparison (1) | Does not favor either the inter- vention or the comparison (1) | Favors the intervention | | No cost-effectiveness studies available. | | |
| Equity | Uncertain (3) | Reduced (2) | Probably no impact (1) | Increased (2) | | No local studies available. | | |
| Acceptability | Uncertain (1) | No (5) | Yes (2) | Varies | | In the survey of 400 adults, 90.75% perceived that face mask is the most effective PPE. 35/400 among adults in Metro Manila believed that face shield is most effective PPE (2) Ease of use Vaccination status should be considered | | |
| | Uncertain | No (1) | Yes (7) | Varies | | No local studies available. | | |

Appendix 6. Evidence to Decision. Summary of initial judgements prior to the actual panel meeting (N = 8)

References:

1. DOH. Updated suggested retail price (SRPs) for emergency essential medicines and medical devices due to the coronavirus disease 2019 (COVID-19) health event. In: Health Do, editor. 2021.

2. Galope F, Co S, Davantes P. A study on the knowledge, attitudes, and practices among adult Filipinos on wearing proper personal protective equipment in Metro Manila during the COVID-19 pandemic. Int J Progress Res Sci Eng. 2021;2:75-91.